Drug General Information (ID: DDI84ZLKG5)
Drug Name			Adenosine		Drug Info		Halothane		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiarrhythmic Agents				Anesthetics
Structure

Mechanism of Adenosine-Halothane Interaction (Severity Level: Moderate)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Adenosine				Halothane
Mechanism 1		Bradycardia				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Adenosine and Halothane
Mechanism 2		Delay atrioventricular conduction				Prolong QT interval
Key Mechanism Factor 2
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Adenosine and Halothane

Recommended Action
Management		Adenosine should be used with caution in patients receiving drugs that may prolong the QT interval. Adenosine should be discontinued immediately if severe bradycardia occurs.

References
1	Canadian Pharmacists Association.
2	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
3	Cerner Multum, Inc. "Australian Product Information.".
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Teodorovich N, Margolin E, Kogan Y, Paz O, Swissa M. Torsades de pointes after adenosine administration. J Electrocardiol. 2016;49(2):171-173. [PMID: 26850499]
6	Harrington GR, Froelich EG "Adenosine-induced torsades de pointes." Chest 103 (1993): 1299-1301. [PMID: 8131497]
7	Mallet ML "Proarrhythmic effects of adenosine: a review of the literature." Emerg Med J 21 (2004): 408-10. [PMID: 15208219]
8	Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75. [PMID: 10926350]
9	Tachakra SS, Robinson S "Adenosine and cardiac arrhythmias." BMJ 305 (1992): 422. [PMID: 1392935]
10	Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992): 794-6. [PMID: 1539535]